S&P 500 6,976.44 ▲ 37.41 (+0.54%)
DOW 49,407.66 ▲ 515.19 (+1.05%)
NASDAQ 23,592.11 ▲ 130.29 (+0.56%)
US Markets Closed

ABPWW

Abpro Holdings Inc

Price Chart
Latest Quote

$0.01

Current Price
Previous Close $0.01
Open $0.02
Day High $0.01
Day Low $0.01
Volume 2,145
Fetched: 2026-02-03T00:14:02
Stock Information
Total Debt $147K
Cash Equivalents $328K
Net Income $-22.04M
Exchange NCM
🌐 Visit Website
📊 Custom Metrics & Score
Score: 13/42
Debt to Equity -0.21
Debt to Earnings -0.46
Current Ratio 0.19
Quick Ratio 0.16
Avg Revenue Growth -30.33%
Profit Margin -3951.91%
Return on Equity 46.67%
Avg FCF Growth 0.05%
Score Explanation: The perfect score is 42/42 based on debt levels, profitability, growth rates, and cash flow metrics. FCF Yield is weighted most heavily as it shows what return the business currently generates.
Recent Price History
Date Close Volume
2026-02-02 $0.01 2,145
About Abpro Holdings Inc

Abpro Holdings, Inc., a biotechnology company, focuses on novel antibody constructs for immuno-oncology and ophthalmology. Its platforms include DiversImmune, a discovery platform that generates a diverse collection of proprietary antibodies against clinically validated and novel targets; and MultiMab, an engineering platform that provides the flexibility to combine antibody building blocks in different combinations and orientations to create fit for purpose novel full-length multi-specific antibody constructs. The company's lead product candidates include ABP-102, a next generation immuno-oncology TetraBi antibody targeting HER2 and CD3 is developed for the treatment of HER2+ solid tumors, including breast and gastric cancers; and ABP-201, a TetraBi antibody format that simultaneously inhibit VEGF and ANG-2 for the treatment of vascular diseases of the eye, including diabetic macular edema and wet age-related macular degeneration. It also develops ABP-110, a TetraBi antibody targeting GPC3 and CD3 for the treatment of hepatocellular carcinoma; and ABP-150, a TetraBi antibody targeting claudin 18.2 and CD3 for the treatment of gastric cancers. The company has strategic partnership with Celltrion Inc. and Abpro Bio International, Inc. Abpro Holdings, Inc. was incorporated in 2004 and is headquartered in Woburn, Massachusetts.

Income Statement (Annual)
Revenue
Metric 2024-12-31 2023-12-31 2022-12-31
Total Revenue $183,000 $122,000 $2,029,000
Operating Revenue $183,000 $122,000 $2,029,000
Expenses
Metric 2024-12-31 2023-12-31 2022-12-31
Interest Expense $387,000 $23,000 $248,000
Total Expenses $10,104,000 $11,868,000 $18,714,000
Other Income Expense $3,067,000 - -
Other Non Operating Income Expenses $3,556,000 - -
Net Non Operating Interest Income Expense $-378,000 $40,000 $-200,000
Interest Expense Non Operating $387,000 $23,000 $248,000
Operating Expense $10,104,000 $11,868,000 $18,714,000
General And Administrative Expense $7,121,000 $7,602,000 $8,960,000
Income & Earnings
Metric 2024-12-31 2023-12-31 2022-12-31
Net Income From Continuing Operation Net Minority Interest $-7,232,000 $-11,706,000 $-17,215,000
Net Interest Income $-378,000 $40,000 $-200,000
Interest Income $9,000 $63,000 $48,000
Normalized Income $-6,743,000 $-11,706,000 $-17,215,000
Net Income From Continuing And Discontinued Operation $-7,232,000 $-11,706,000 $-17,215,000
Total Operating Income As Reported $-9,921,000 $-11,746,000 $-16,685,000
Net Income Common Stockholders $-17,409,000 $-11,706,000 $-17,215,000
Net Income $-7,232,000 $-11,706,000 $-17,215,000
Net Income Including Noncontrolling Interests $-7,232,000 $-11,706,000 $-17,215,000
Net Income Continuous Operations $-7,232,000 $-11,706,000 $-17,215,000
Pretax Income $-7,232,000 $-11,706,000 $-16,885,000
Special Income Charges $173,000 $0 -
Interest Income Non Operating $9,000 $63,000 $48,000
Operating Income $-9,921,000 $-11,746,000 $-16,685,000
Other
Metric 2024-12-31 2023-12-31 2022-12-31
Tax Effect Of Unusual Items $0 $0 $0
Tax Rate For Calcs $0 $0 $0
Normalized EBITDA (Bullshit earnings) $-5,734,000 $-10,891,000 $-15,781,000
Total Unusual Items $-489,000 $0 -
Total Unusual Items Excluding Goodwill $-489,000 $0 -
Reconciled Depreciation $622,000 $792,000 $856,000
EBITDA (Bullshit earnings) $-6,223,000 $-10,891,000 $-15,781,000
EBIT $-6,845,000 $-11,683,000 $-16,637,000
Diluted NI Availto Com Stockholders $-17,409,000 $-11,706,000 $-17,215,000
Otherunder Preferred Stock Dividend $10,177,000 $0 -
Other Special Charges $-173,000 - -
Gain On Sale Of Security $-662,000 - -
Research And Development $2,983,000 $4,266,000 $9,754,000
Selling General And Administration $7,121,000 $7,602,000 $8,960,000
Other Gand A $7,121,000 $7,602,000 $8,960,000
Tax Provision - $0 $330,000
Fetched: 2026-02-02
Balance Sheet (Annual)
Assets
Metric 2024-12-31 2023-12-31 2022-12-31
Net Tangible Assets $-15,671,000 $-89,170,000 $-76,479,000
Total Assets $4,661,000 $3,355,000 $11,852,000
Total Non Current Assets $885,000 $1,320,000 $2,205,000
Non Current Prepaid Assets $66,000 $66,000 $66,000
Financial Assets $188,000 $0 -
Goodwill And Other Intangible Assets $176,000 $186,000 $196,000
Other Intangible Assets $176,000 $186,000 $196,000
Current Assets $3,776,000 $2,035,000 $9,647,000
Other Current Assets $306,000 $208,000 $292,000
Hedging Assets Current $155,000 $0 -
Current Deferred Assets $0 $878,000 $0
Restricted Cash $142,000 $138,000 -
Receivables $323,000 $88,000 $2,030,000
Accounts Receivable $323,000 $88,000 $2,030,000
Cash Cash Equivalents And Short Term Investments $2,850,000 $723,000 $7,325,000
Cash And Cash Equivalents $2,850,000 $723,000 $7,325,000
Cash Financial $2,850,000 $723,000 $7,325,000
Other Non Current Assets - $138,000 $137,000
Non Current Note Receivables - $0 $4,000
Debt
Metric 2024-12-31 2023-12-31 2022-12-31
Net Debt $22,000 $1,019,000 -
Total Debt $3,328,000 $2,894,000 $1,874,000
Long Term Debt And Capital Lease Obligation $0 $455,000 $1,119,000
Current Debt And Capital Lease Obligation $3,328,000 $2,439,000 $755,000
Current Debt $2,872,000 $1,742,000 -
Other Current Borrowings $2,725,000 - -
Liabilities
Metric 2024-12-31 2023-12-31 2022-12-31
Total Liabilities Net Minority Interest $19,607,000 $91,790,000 $87,586,000
Total Non Current Liabilities Net Minority Interest $0 $76,054,000 $76,718,000
Current Liabilities $19,607,000 $15,736,000 $10,868,000
Other Current Liabilities $80,000 - -
Current Notes Payable $147,000 $1,742,000 $0
Payables And Accrued Expenses $16,199,000 $13,297,000 $10,049,000
Interest Payable $267,000 - -
Payables $8,703,000 $7,916,000 $8,152,000
Total Tax Payable $4,767,000 $0 -
Income Tax Payable $366,000 $0 -
Accounts Payable $3,936,000 $7,916,000 $8,152,000
Current Deferred Liabilities - $0 $64,000
Equity
Metric 2024-12-31 2023-12-31 2022-12-31
Common Stock Equity $-15,495,000 $-88,984,000 $-76,283,000
Total Equity Gross Minority Interest $-14,946,000 $-88,435,000 $-75,734,000
Stockholders Equity $-15,495,000 $-88,984,000 $-76,283,000
Retained Earnings $-116,103,000 $-108,871,000 $-93,865,000
Preferred Securities Outside Stock Equity $0 $75,599,000 $75,599,000
Other
Metric 2024-12-31 2023-12-31 2022-12-31
Treasury Shares Number $983,333 - -
Ordinary Shares Number $50,832,432 $50,535,272 $50,535,272
Share Issued $51,815,765 $50,535,272 $50,535,272
Tangible Book Value $-15,671,000 $-89,170,000 $-76,479,000
Invested Capital $-12,623,000 $-87,242,000 $-76,283,000
Working Capital $-15,831,000 $-13,701,000 $-1,221,000
Capital Lease Obligations $456,000 $1,152,000 $1,874,000
Total Capitalization $-15,495,000 $-88,984,000 $-76,283,000
Minority Interest $549,000 $549,000 $549,000
Treasury Stock $0 $33,000 $33,000
Additional Paid In Capital $100,603,000 $19,918,000 $17,606,000
Capital Stock $5,000 $2,000 $9,000
Common Stock $5,000 $2,000 $9,000
Long Term Capital Lease Obligation $0 $455,000 $1,119,000
Current Capital Lease Obligation $456,000 $697,000 $755,000
Current Accrued Expenses $7,496,000 $5,381,000 $1,897,000
Net PPE $455,000 $1,068,000 $1,802,000
Accumulated Depreciation $-2,656,000 $-2,591,000 $-2,322,000
Gross PPE $3,111,000 $3,659,000 $4,124,000
Leases $788,000 $788,000 $788,000
Other Properties $2,255,000 $2,803,000 $3,268,000
Machinery Furniture Equipment $68,000 $68,000 $68,000
Properties $0 $0 $0
Current Deferred Revenue - $0 $64,000
Fetched: 2026-02-02
Cash Flow Statement (Annual)
Free Cash Flow
Metric 2024-12-31 2023-12-31 2022-12-31
Free Cash Flow $-9,030,000 $-7,450,000 $-9,017,000
Operating Activities
Metric 2024-12-31 2023-12-31 2022-12-31
Operating Cash Flow $-9,030,000 $-7,402,000 $-8,952,000
Cash Flow From Continuing Operating Activities $-9,030,000 $-7,402,000 $-8,952,000
Operating Gains Losses $177,000 - -
Investing Activities
Metric 2024-12-31 2023-12-31 2022-12-31
Investing Cash Flow $0 $-48,000 $-65,000
Cash Flow From Continuing Investing Activities $0 $-48,000 $-65,000
Capital Expenditure - $-48,000 $-65,000
Financing Activities
Metric 2024-12-31 2023-12-31 2022-12-31
Issuance Of Capital Stock $10,361,000 $0 $9,991,000
Financing Cash Flow $11,161,000 $849,000 $9,784,000
Cash Flow From Continuing Financing Activities $11,161,000 $849,000 $9,784,000
Net Other Financing Charges $-952,000 $-371,000 -
Net Common Stock Issuance $10,361,000 $0 -
Common Stock Issuance $10,361,000 $0 -
Net Preferred Stock Issuance - $0 $9,991,000
Preferred Stock Issuance - $0 $9,991,000
Other
Metric 2024-12-31 2023-12-31 2022-12-31
Repayment Of Debt $-5,752,000 $-222,000 $-207,000
Issuance Of Debt $8,638,000 $1,442,000 $0
Interest Paid Supplemental Data $1,000 $16,000 $30,000
End Cash Position $2,992,000 $861,000 $7,462,000
Beginning Cash Position $861,000 $7,462,000 $6,695,000
Changes In Cash $2,131,000 $-6,601,000 $767,000
Proceeds From Stock Option Exercised $-1,134,000 $0 -
Net Issuance Payments Of Debt $2,886,000 $1,220,000 $-207,000
Net Short Term Debt Issuance $2,903,000 $1,442,000 $0
Short Term Debt Payments $-5,735,000 $0 -
Short Term Debt Issuance $8,638,000 $1,442,000 $0
Net Long Term Debt Issuance $-17,000 $-222,000 $-207,000
Long Term Debt Payments $-17,000 $-222,000 $-207,000
Net PPE Purchase And Sale $0 $-48,000 $0
Purchase Of PPE $0 $-48,000 $0
Change In Working Capital $-1,319,000 $1,207,000 $3,389,000
Change In Other Current Liabilities $-566,000 $-500,000 $-440,000
Change In Payables And Accrued Expense $-420,000 $-259,000 $5,790,000
Change In Accrued Expense $383,000 $484,000 $-454,000
Change In Payable $-803,000 $-743,000 $6,244,000
Change In Account Payable $-860,000 $-743,000 $6,244,000
Change In Tax Payable $57,000 $0 -
Change In Income Tax Payable $57,000 $0 -
Change In Prepaid Assets $-98,000 $84,000 $-35,000
Change In Receivables $-235,000 $1,946,000 $-1,990,000
Changes In Account Receivables $-235,000 $1,942,000 $-1,990,000
Other Non Cash Items $-3,205,000 - -
Stock Based Compensation $1,927,000 $2,305,000 $4,018,000
Depreciation Amortization Depletion $622,000 $792,000 $856,000
Depreciation And Amortization $622,000 $792,000 $856,000
Depreciation $622,000 $792,000 $856,000
Gain Loss On Investment Securities $350,000 - -
Net Income From Continuing Operations $-7,232,000 $-11,706,000 $-17,215,000
Net Intangibles Purchase And Sale - $0 $-65,000
Purchase Of Intangibles - $0 $-65,000
Change In Other Working Capital - $-64,000 $64,000
Fetched: 2026-02-02